FindTrial
Sign In

Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations

A Prospective Study of Sulfonylureas in Patients With Diabetes Due to Kir6.2 Mutations

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00334711
Enrollment
50
Registered
2006-06-08
Start date
2004-01-31
Completion date
2006-01-31
Last updated
2006-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Permanent Neonatal Diabetes, Kir6.2, KCNJ11, Infancy onset diabetes, Sulfonylurea

Brief summary

The purpose of this study is to investigate whether patients with diabetes due to Kir6.2 mutations can be treated with sulfonylurea medication rather than insulin, and if this is the case to investigate the mechanism for sulfonylurea response.

Interventions

DRUGSulfonylurea

Sponsors

Wellcome Trust
CollaboratorOTHER
Hôpital Necker-Enfants Malades
CollaboratorOTHER
Haukeland University Hospital
CollaboratorOTHER
Royal Devon and Exeter NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Diabetes due to KCNJ11 (Kir6.2) mutation

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
HbA1c reduction—

Secondary

MeasureTime frame
insulin secretory response to intravenous glucose—
insulin secretory response to oral glucose—
insulin secretory response to mixed meal (sustacal)—
Incidence of Hypoglycemia—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 11, 2026